物质信息
ID:428
名称和标识
商标名
RegonolMestinon-SRMestinon
IUPAC标准名
3-[(dimethylcarbamoyl)oxy]-1-methylpyridin-1-ium
别名
Pyridostigmine BrominePyridostigminePyridostigmine BromidePyridine N-OxidePyridostigminum
IUPAC传统名
pyridostigmine
化合物性质
理化性质
疏水性(logP)
1.554
溶解度
1.04 mg/mL [Predicted by ALOGPS]
描述信息
Drug Groups
approved
Description
A cholinesterase inhibitor with a slightly longer duration of action than neostigmine. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants. [PubChem]
Indication
For the treatment of myasthenia gravis.
Pharmacology
Pyridostigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. Since it is a quaternary amine, it is poorly absorbed in the gut and doesn't cross the blood-brain barrier. Pyridostigmine has a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.
Affected Organisms
Humans and other mammals
Biotransformation
Hydrolysis by cholinesterases and by liver.
Absorption
Poorly absorbed from the GI tract with an oral bioavailability of 7.6 +/- 2.4%.
Half Life
3 hours following oral administration.
References
•
Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA: Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1294-8.
[Pubmed]
External Links
分子图谱
暂无数据
点击上传数据
参考文献
• Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA: Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1294-8. Pubmed